155 related articles for article (PubMed ID: 35796846)
1. Accuracy of tumor registry versus pharmacy dispensings for breast cancer adjuvant endocrine therapy.
Haas CB; Bowles EJA; Lee JM; Specht J; Buist DSM
Cancer Causes Control; 2022 Sep; 33(9):1145-1153. PubMed ID: 35796846
[TBL] [Abstract][Full Text] [Related]
2. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
3. Patterns of care analysis among women with ductal carcinoma in situ in North Carolina.
Jackson LC; Camacho F; Levine EA; Anderson RT; Stewart JH
Am J Surg; 2008 Feb; 195(2):164-9. PubMed ID: 18096124
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen Initiation After Ductal Carcinoma In Situ.
Nichols HB; Bowles EJ; Islam J; Madziwa L; Stürmer T; Tran DT; Buist DS
Oncologist; 2016 Feb; 21(2):134-40. PubMed ID: 26768485
[TBL] [Abstract][Full Text] [Related]
5. Treatment of breast cancer in countries with limited resources.
Carlson RW; Anderson BO; Chopra R; Eniu AE; Jakesz R; Love RR; Masetti R; Schwartsmann G;
Breast J; 2003; 9 Suppl 2():S67-74. PubMed ID: 12713499
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival.
Schonberg MA; Marcantonio ER; Li D; Silliman RA; Ngo L; McCarthy EP
J Clin Oncol; 2010 Apr; 28(12):2038-45. PubMed ID: 20308658
[TBL] [Abstract][Full Text] [Related]
7. Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001-2016.
Bowles EJA; Ramin C; Buist DSM; Feigelson HS; Weinmann S; Veiga LHS; Bodelon C; Curtis RE; Vo JB; Berrington de Gonzalez A; Gierach GL
Breast Cancer Res Treat; 2022 May; 193(1):203-216. PubMed ID: 35275285
[TBL] [Abstract][Full Text] [Related]
8. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
[TBL] [Abstract][Full Text] [Related]
10. Are there changes in characteristics and therapy of young patients with early-onset breast cancer in Germany over the last decade?
Banz-Jansen C; Heinrichs A; Hedderich M; Waldmann A; Wedel B; Mebes I; Diedrich K; Rody A; Fischer D
Arch Gynecol Obstet; 2013 Aug; 288(2):379-83. PubMed ID: 23407999
[TBL] [Abstract][Full Text] [Related]
11. Endocrine Therapy Initiation and Medical Oncologist Utilization Among Women Diagnosed with Ductal Carcinoma in Situ.
Anderson C; Meyer AM; Wheeler SB; Zhou L; Reeder-Hayes KE; Nichols HB
Oncologist; 2017 May; 22(5):535-541. PubMed ID: 28408621
[TBL] [Abstract][Full Text] [Related]
12. Discontinuation of radiation treatment among medicaid-enrolled women with local and regional stage breast cancer.
Ramsey SD; Zeliadt SB; Richardson LC; Pollack LA; Linden H; Blough DK; Cheteri MK; Tock L; Nagy K; Anderson N
Breast J; 2010; 16(1):20-7. PubMed ID: 19929888
[TBL] [Abstract][Full Text] [Related]
13. Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy.
Giannakeas V; Sopik V; Narod SA
JAMA Netw Open; 2018 Aug; 1(4):e181100. PubMed ID: 30646103
[TBL] [Abstract][Full Text] [Related]
14. Endocrine therapy initiation and overall survival outcomes with omission of radiation therapy in older Medicare patients with early-stage hormone-receptor-positive breast cancer.
Shen C; Li N; Zhou S; Stahl K; Dodge D; Zhao H
Cancer Med; 2023 Mar; 12(6):6935-6944. PubMed ID: 36428284
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant Radiation Improves Survival in Older Women Following Breast-Conserving Surgery for Estrogen Receptor-Negative Breast Cancer.
Daugherty EC; Daugherty MR; Bogart JA; Shapiro A
Clin Breast Cancer; 2016 Dec; 16(6):500-506.e2. PubMed ID: 27431462
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy use and surgical treatment by receptor subtype in node-negative T1a and T1b female breast cancers, Iowa SEER Registry, 2010 to 2012.
Schroeder MC; Lynch CF; Abu-Hejleh T; Chrischilles EA; Thomas A
Clin Breast Cancer; 2015 Feb; 15(1):e27-34. PubMed ID: 25245424
[TBL] [Abstract][Full Text] [Related]
17. Association of Diabetes and Other Clinical and Sociodemographic Factors With Guideline-concordant Breast Cancer Treatment for Breast Cancer.
Gold HT; Shao H; Oratz R; Yu O; Hammer M; Richardson S; Boudreau D
Am J Clin Oncol; 2020 Feb; 43(2):101-106. PubMed ID: 31850918
[TBL] [Abstract][Full Text] [Related]
18. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
Toi M; Imoto S; Ishida T; Ito Y; Iwata H; Masuda N; Mukai H; Saji S; Shimizu A; Ikeda T; Haga H; Saeki T; Aogi K; Sugie T; Ueno T; Kinoshita T; Kai Y; Kitada M; Sato Y; Jimbo K; Sato N; Ishiguro H; Takada M; Ohashi Y; Ohno S
Lancet Oncol; 2021 Jan; 22(1):74-84. PubMed ID: 33387497
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
